Join us this morning at 11am for the laun... - Leukaemia CARE

Leukaemia CARE

904 members505 posts

Join us this morning at 11am for the launch or the Acute Myeloid Leukaemia (AML) North of England Virtual Support Group

HAIRBEAR_UK
HAIRBEAR_UKAdministrator

10th August at 11am – Launch meeting – Hosted by Jessica Turner, Leukaemia Care North-West Regional Coordinator.

Our Acute Myeloid Leukaemia (AML) North Virtual Support Group is for anyone who has been diagnosed with AML in the North of England. Our meetings are a great way for you to meet someone who is going through or has been through the same journey as you. .

Guest: Laura de la Harpe, Registered Nutritional Therapist and Nutritionist

If you would like to attend this group, please register your attendance online here. leukaemiacare.org.uk/virtua...

If you would like further information or if you would like to attend, please contact our Patient Services Team on freephone 08088 010 444 (Monday – Friday, 9am-5pm) or email support@leukaemiacare.org.uk

2 Replies
oldestnewest

My Thoughts on the Future of FLT3 Therapy in AML

CME by Naval G. Daver, MD

Source: Current and Future Treatment Strategies for Acute Myeloid Leukemia

(See clinicaloptions.com/oncolog...)

Gain insight on the latest investigative treatments for patients with FLT3-positive AML with this expert commentary.

"Approximately 25% of patients with acute myeloid leukemia (AML) have the FLT3-ITD or FLT3-TKD mutation, which is prognostic for poorer outcomes. In the past 4 years, the FDA approved 2 FLT3 inhibitors, midostaurin and gilteritinib. Midostaurin was approved in combination with standard 3+7 induction chemotherapy, in a randomized, multicentral phase III study of 3+7 with midostaurin vs 3+7 alone in patients with newly diagnosed FLT3-ITD and/or DA35 mutations in the frontline setting. Gilteritinib is a more potent and specific second-generation FLT3 inhibitor and was approved based on improved survival as well as improved composite CR (CRc) rate, noted in the phase III Admiral study in patients with relapsed/refractory FLT3-ITD–mutated and/or D835-mutated AML, in which gilteritinib was compared with investigator choice chemotherapy, and gilteritinib showed a significantly improved CRc rate of 35% vs 15% for chemotherapy."

Caven

2003UK
2003UKChampion

Sorry I could not make this Hairbear, thanks for letting us know and I hope it went well, take care of yourself.

You may also like...